TheraRadar
Data updated: May 26, 2026

LAZANDA (fentanyl citrate)

Trial Activity: Mature 3 active trials
Pain Approved 2011-06-30
Jump to: Indications Approvals Trials Competitors Safety Patents

Development Insights

Women's Hospital HUS conducting 2 trials (12%)
23 indications explored (Broad Platform)
→ labor pain (2 trials)
→ induced; birth (2 trials)
→ pain (2 trials)
1
Indication
--
Phase 3 Trials
14
Years on Market

Details

Status
Discontinued
First Approved
2011-06-30
Patent Cliff
2032

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
NASAL
Dosage Forms
SPRAY, METERED

Companies

BTCP PHARMA
Active Ingredient: FENTANYL CITRATE

LAZANDA Approval History

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
69 FDA actions from 2011 to 2022
Dec 2022 SUPPL
Update · REMS
FDA Letter
Aug 2022 SUPPL
Update · REMS
FDA Letter
Dec 2021 SUPPL
Update · REMS
FDA Letter

What LAZANDA Treats

1 FDA approvals

Originally approved for its first indication in 2011 .

  • Other (1)
📋

Clinical Trial Registry

16 trials
Trial Sponsor ID Phase Status Title
NCT05437575 PAIN STUDY22010164 HT9425-25-F-0041 Ph 3 recruiting Prehospital Analgesia INtervention Trial (PAIN)
NCT06051227 FORE-PAIN FP-2023 2022-500176-63-00, U1111-1287-7486 Ph 3 recruiting Fentanyl or Esketamine for Traumatic PAIN (FORE-PAIN) Trial
NCT04645823 Versio4_22112020 2020-005506-26 Ph 4 completed Spinal Fentanyl or Epidural Analgesia in the Early First Phase of Induced Labor
NCT03018756 DMED-1921-16 Ph 3 completed Nebulized Fentanyl in Patients With Mild to Moderate Interstitial Lung Disease and Chronic Dyspnea
NCT03405090 DMED-1926-16 Ph 4 completed Differential Mechanisms of Dyspnea Relief in Advanced COPD: Opiates vs. Bronchodilators
NCT06017141 STUDY00149314 NCI-2023-05587, IIT-2022-VIVA Ph 2 recruiting Inhalational or Intravenous Anesthesia During Surgery for Patients With Colon Cancer, VIVA Study
NCT03809455 FARADI UC-0106/1607 SdS 02 FARADI Ph 2 withdrawn Effectiveness and Tolerance of Fentanyl Citrate in Painful Pain Induced During Diagnostic or Therapeutic Examinations in Cancer Patients
NCT03071744 results posted UCSD 161263 Ph 2 terminated Lazanda in Cancer Patients Receiving Palliative Radiation
NCT01516684 results posted IRB00017079 NCI-2012-00019, CCCWFU 01211 Ph 2 completed Local Anesthetic Cream in Younger Patients Undergoing Lumbar Punctures
NCT03682211 SCC01 2011-005161-20, ISRCTN67469672 Ph 4 completed Intranasal Fentanyl Versus Intravenous Morphine in the Treatment of Severe Painful Sickle Cell Crises in Children
NCT02571634 RFA results posted 404457 Ph 4 completed Lazanda Fentanyl Nasal Spray Pre Radiofrequency Nerve Ablations(RFA) of Lumbar Facet Joints
NCT01482091 results posted 11-09-343 Ph 4 completed Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis
NCT02576353 INS002-15-049 Ph 1 completed Fentanyl Sublingual Spray and Fentanyl Citrate Intravenous (IV) in Opioid Naive Subjects
NCT01308320 4-2009-0111 Ph 4 completed Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia
NCT00795314 PABADUC NMU-2008-FY10MZ31 NJFY0811-MZ02 Ph 4 completed Propofol-butorphanol Anesthesia During Uterine Curettage
NCT00738192 CARAN NMU-FY2008-311 NJFY0807311M Ph 4 completed Comparison of Analgesic Efficacy of Fentanyl, Sufentanil and Butorphanol After Remifentanil Anesthesia
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LAZANDA FDA Label Details

View full patent landscape →
1 OB patents · 1 families · 32 international docs across 25 countries

LAZANDA Patents & Exclusivity

Latest Patent: Jan 2032

Patents (1 active)

US9731869 Expires Jan 26, 2032
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for LAZANDA

Revenue Insights

  • • Quarterly revenue tracking
  • • Historical trend analysis

Patent Timeline

  • • Cliff: 2032
  • • 9 active patents

Trial Analysis

  • • 17 total trials
  • • Stage: Mature

Competitive Landscape

  • • Competitor tracking
  • • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

FDA Approval: NDA022569 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.

How We Calculate These Metrics

Trial Activity Stage

Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.

Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.

  • Growth: High proportion of early-phase trials (Phase 1/2), active development
  • Expansion: Significant Phase 3 activity, approaching or pursuing approvals
  • Mature: Substantial Phase 4 post-marketing studies
  • Stable: Mixed phase distribution, steady development
  • Declining: Low active trial ratio, reduced R&D investment